RxDoctor Payments Data

Mariam Subeih

Family · Dearborn, MINPI 1972288892

Payments from drug & device makers

$239in general payments, 2019–2025

Across 12 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius Kabi USA, LLC$119
  • Lilly USA, LLC$29
  • Exact Sciences$21
  • Vivaquant Inc, Dba Rhythm Express$20
  • Dexcom, Inc.$19
  • AstraZeneca$18
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$239100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Fresenius Kabi USA, LLC5$119
Lilly USA, LLC2$29
Exact Sciences1$21
Vivaquant Inc, Dba Rhythm Express1$20
Dexcom, Inc.1$19
AstraZeneca1$18
Novo Nordisk1$13

How this compares

$239 in reported general payments places this provider in the 40th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$491,592
Medicare patients
86
Services billed
47,847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin61$38,669
JanuviaSitagliptin Phosphate40$30,124
TrulicityDulaglutide31$29,993
OzempicSemaglutide28$27,477
FarxigaDapagliflozin Propanediol40$22,521
EliquisApixaban30$21,504
XareltoRivaroxaban18$14,561
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,065
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$2,543
Albuterol Sulfate HfaAlbuterol Sulfate78$2,079
Esomeprazole Magnesium17$1,876
Atorvastatin Calcium187$1,247
Ventolin HfaAlbuterol Sulfate23$1,233
FenofibrateFenofibrate Nanocrystallized19$946
Fluticasone Propionate77$836

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$29$29,99331 claims
Novo NordiskOzempic$13$27,47728 claims
AstraZenecaFarxiga$18$22,52140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 3,657 family providers in Michigan.

Other family in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →